Replimune Group, Inc. (NASDAQ:REPL) Stake Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 4.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 508,398 shares of the company's stock after buying an additional 23,601 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.74% of Replimune Group worth $6,157,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock valued at $15,657,000 after purchasing an additional 217,308 shares in the last quarter. Barclays PLC raised its stake in shares of Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company's stock valued at $1,738,000 after acquiring an additional 98,791 shares during the period. State Street Corp boosted its position in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company's stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the period. Baker BROS. Advisors LP increased its holdings in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock valued at $121,057,000 after purchasing an additional 1,000,000 shares in the last quarter. Finally, Braidwell LP raised its position in Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company's stock valued at $33,656,000 after purchasing an additional 2,057,460 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Replimune Group Stock Performance

REPL traded down $0.06 during trading hours on Friday, hitting $10.39. 368,583 shares of the stock were exchanged, compared to its average volume of 859,240. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $17.00. The stock has a 50-day simple moving average of $12.67 and a 200-day simple moving average of $12.14. The stock has a market cap of $800.19 million, a price-to-earnings ratio of -3.38 and a beta of 1.30.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). Analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

REPL has been the topic of several analyst reports. BMO Capital Markets raised their target price on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. HC Wainwright raised their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Finally, Jefferies Financial Group boosted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, December 4th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.